Drug Delivery, Cancer
The company is a medical device company that has developed a cutting edge catheter-based drug delivery technology that enables the delivery of drugs to highly […]
Month: June 2010
Diagnostics
The company is a medical devices company that has developed advanced diagnostic technology for detection of bacterial infections and their antibiotic susceptibility. The company’s novel […]
Making Reimbursement Work In a Post-Healthcare Reform World
The passage of healthcare reform in March brought a wave of reimbursement-related headaches to the life science industry.
[OneMedForum] MacuCLEAR Sees Unmet Need for Vision-Loss Treatment
With the large Baby Boomer population reaching its senior years, the incidence of age-related vision loss in the U.S. is expected to increase.
OneMedPlace Announces Panel Discussions and Workshops for “2010 New York OneMedForum”
The goal of the “2010 New York OneMedForum” is to connect private and public (microcap) medtech, biotech and health information companies with a global group of active healthcare investors.
The Value of Intellectual Property
Even before a drug or medical device reaches blockbuster status, protecting intellectual property should still be a priority.
How to Get Noticed by Big Pharma
Less than 15 percent of unsolicited inquiries to Big Pharma actually get reviewed.
How can a pharmaceutical startup grab the attention of Big Pharma?
Father’s Day Draws Attention to Prostate Cancer
Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
Leading New York Research Institutions to Showcase at OneMedForum
OneMedPlace announced that the leading Universities and Hospitals in the New York area will showcase their most promising medical technologies June 30th at the OneMedForum NY 2010 in Midtown Manhattan.
Workshop to Show Companies How to Navigate FDA Approval Process
Tougher FDA requirements for the drug approval process, implemented in the wake of the Vioxx disaster, have added confusion–and, according to drug companies, delays–into the mix for many pharmaceutical manufacturers. With the new requirements, drug developers may be unsure of what to file and how to file.